Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 5;11(3):181.
doi: 10.3390/jpm11030181.

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia

Affiliations

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia

Diana Z Paderina et al. J Pers Med. .

Abstract

Background: Antipsychotic-induced metabolic syndrome (MetS) is a multifactorial disease with a genetic predisposition. Serotonin and its receptors are involved in antipsychotic-drug-induced metabolic disorders. The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor (HTR) genes HTR1A, HTR2A, HTR3A, and HTR2C and the gene encoding for the serotonin transporter SLC6A4 with MetS in patients with schizophrenia.

Methods: A set of nine single-nucleotide polymorphisms of genes of the serotonergic system was investigated in a population of 475 patients from several Siberian regions (Russia) with a clinical diagnosis of schizophrenia. Genotyping was performed and the results were analyzed using chi-square tests.

Results: Polymorphic variant rs521018 (HTR2C) was associated with higher body mass index in patients receiving long-term antipsychotic therapy, but not with drug-induced metabolic syndrome. Rs1150226 (HTR3A) was also associated but did not meet Hardy-Weinberg equilibrium.

Conclusions: Our results indicate that allelic variants of HTR2C genes may have consequences on metabolic parameters. MetS may have too complex a mechanistic background to be studied without dissecting the syndrome into its individual (causal) components.

Keywords: antipsychotics; body mass index; genes; metabolic syndrome; pharmacogenetics; schizophrenia; serotonin; weight gain.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Similar articles

Cited by

References

    1. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011;8:114–126. doi: 10.1038/nrendo.2011.156. - DOI - PubMed
    1. O’Neill S., O’Driscoll L. Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies. Obes. Rev. 2015;16:1–12. doi: 10.1111/obr.12229. - DOI - PubMed
    1. Rojo L.E., Gaspar P.A., Silva H., Risco L., Arena P., Cubillos-Robles K., Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol. Res. 2015;101:74–85. doi: 10.1016/j.phrs.2015.07.022. - DOI - PubMed
    1. Freyberg Z., Aslanoglou D., Shah R., Ballon J.S. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Front. Neurosci. 2017;11:432. doi: 10.3389/fnins.2017.00432. - DOI - PMC - PubMed
    1. Ijaz S., Bolea B., Davies S., Savović J., Richards A., Sullivan S., Moran P. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: A review of systematic reviews. BMC Psychiatry. 2018;18:275. doi: 10.1186/s12888-018-1848-y. - DOI - PMC - PubMed

LinkOut - more resources